Sun Pharma to buy Ranbaxy

Share this article:

Generics maker Sun Pharmaceutical is buying Daiichi Sankyo's generics firm Ranbaxy, which is based in India. Reuters reports that Daiichi Sankyo will get 0.8 Sun Pharma shares for each Ranbaxy share.

The news follows a slate of bad news about generics made in India, including the FDA banning products from four Ranbaxy sites. The FDA has defended generics made in India and has said it is working with the country's regulatory agency to bring up standards and manufacturing scrutiny.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Imbruvica lassoes CLL indication

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February.

FDA asks social media "how'm I doin?"

The FDA's Center for Drug Evaluation and Research's Office of Communications wants a system that will help assess its messaging reach across the interwebs and its many forums.

Reckitt Benckiser wants out of pharma

The company plans to spin off its pharmaceutical unit.